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S.M.CHANNABASAVANNA 
Respected President of the Indian Psychi-
atric Society, Members of the Chair, Members of 
the Awards Committee, distinguished colleagues 
and friends, 
I wish to express my gratitude to the 
Chairperson and the members of the Awards 
Committee of the Indian Psychiatric Swiety for 
having bestowed upon me the honour of deliver-
ing the 1996 DLN Murti Rao Oration to this 
august audience. 
Prof. D.L.N. Murti Rao was a great clini-
cian and a psychiatrist with far vision. He was 
also a dedicated teacher; I am proud to be able to 
say that I had been his student during 1958-1960. 
His concern for the postgraduate trainee was 
enormous, as I can vouch from my personal 
experience; I am deeply indebted to Dr. Murti 
Rao for his mentorship during my early days. 
Dr. Murti Rao laid emphasis on adminis-
trative and forensic aspects of psychiatry with a 
view to develop the mental health services in the 
country. He started the outpatient department in 
the Mental Hospital at Bangalore in the early 
1950s, and also initiated an outpatient unit in 
Victoria Hospital, which is a government hospital 
in this same city. I also recall the zeal with which 
he identified postgraduate students in different 
places with a view to train them into senior 
psychiatrists in their respective states. 
In addition, Dr. Murti Rao was fundamen-
tally a biologically-oriented cli.iician with a keen 
sense of observation. To the best of my knowl-
edge, he was the first to use modified electrocon-
vulsive therapy (ECT) in this country; it is a 
matter of regret that the practice which he initiat-
ed is yet to become universal in India. 
In view of his commitment to the progress 
of biological psychiatry, I have selected 'Drug 
Therapy in India: Contemporary issues in the 
quality of care' as my topic for the oration 
dedicated to his name. 
Background 
I began my career in 1958 at the Mental 
Hospital, Bangalore, which is how NIMHANS 
was known in those days. The medical pharma-
copoeia at that time had little to offer to (he 
psychiatrist. The anti-manic property of lithium 
had just been described by Cade (in 1949), and 
the antipsychotic effect of chlorproma/.inc by 
Delay and Deniker (in 1952). 
Prior to the introduction of psychotropic 
agents, we had had to rely on nonspecific central 
nervous system stimulants, sedatives and de-
pressants to treat patients with psychiatric dys-
function. I recall having used amphetamines to 
treat depression, and paraldehyde, bromides, 
chloral hydrate and barbiturates lor manic and 
excited schizophrenic patients. ECT was of 
course much in use as it was the only specific 
and effective therapy available then 
Chlorproma/ine, the first neuroleptic, was 
the also the first neuroleptic to reach us. We had 
little experience with the drug and, despite our 
excitement at having a meaningful therapeutic 
modality at last, used it with great caution; one 
of our anxieties was the risk for the development 
of hypotension. It was common for doses as 
low as 25 mg once to thrice per day to be 
prescribed, and the highest dose in those early 
times was |u«t 100 mg per dav' Nevertheless. 
we had our measure of successes with therapy, 
and this emboldened us to treat patients with 
greater confidence and higher doses. 
Imipramine, the first tricyclic antidepres-
sant drug, introduced by Kuhn in 1958, was also 
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the first antidepressant drug to reach India, around 
1960. The floodgates then opened and, one by 
one, other neuroleptic and antidepressant drugs 
entered the Indian market. Today, the practising 
clinician has a wide variety of psychotropic agents 
to choose from; this wide choice is often taken 
for granted, and only psychiatrists belonging to 
my generation will realize the good fortune of 
clinicians who graduate in psychiatry in the present 
psychopharmacological era. Having had the op-
portunity to see the old and the new across four 
decades of heady progress, I wish to consider in 
this oration issues in the drug therapy of the 
mentally ill that are of concern to contemporary 
Indian psychiatry. 
Pharmacoeducational aspects of the psychia-
trist's prescription: Medicolegal issues and 
the quality of care 
Many of you may be aware that legal and 
forensic aspects of psychiatry are among my 
especial areas of interest. In this context, I wish 
to draw your attention to an event that is likely to 
have far-reaching repercussions on medical prac-
tice in this country. On November 13, 1995, a 
three-member bench of the Supreme Court of 
India delivered a historic 65 page verdict that will 
place several of the issues that I will be discuss-
ing into greater context. The court held that 
service rendered to a patient by a medical practi-
tioner (except where the doctor renders service 
free of charge to every patient or under a con-
tract of personal service) by way of consultation, 
diagnosis and treatment, both medical and surgi-
cal, would fall within the ambit of 'service' as 
defined under the Consumer Protection Act. In 
effect, patients who receive incompetent treat-
ment from either doctors or hospitals can claim 
damages under the Consumer Protection Act in 
the same way that they were entitled to do so for 
negligence. 
I do not propose to discuss all the ramifi-
cations of this judgement, nor all the implications 
for practice; however, I do wish to emphasize 
that the moral responsibility of the clinician to 
provide rational, client-centred pharmacotherapy 
(pardon the pun on the Rogerian approach) may 
now have become a legal obligation. 
In former days, doctors used to be re-
garded as mini-gods. I regret to say that, even 
today, I hear of practitioners who continue to 
exhibit traits of divinity. In the contemporary 
era, a clinician clearly violates his patient's rights 
if his attitude is "I know best; it is unnecessary 
for the patient or the relatives to be part of the 
decision-making processes; they should have 
trust in me, not ask questions." 
While I will discuss the academic and 
practical aspects of drug prescription in a later 
section, here I would like to address the ques-
tion, "What should the patient be told when he 
receives his prescription?" The answer to this 
question has considerable impact on the quality 
of care provided to the patient, and to medicolegal 
issues arising therefrom. 
The psychoeducational approach in psy-
chiatry is well known. I wish to highlight the 
importance of a pharmacoeducational approach 
as well. In the pharmacoeducational model that I 
propose, the patient and/or a key relative (de-
pending upon circumstances) should ideally re-
ceive a basic understanding of 
(a) the need for the prescription, 
(b) the likely benefits from the prescription, 
(c) the likely short-term and long-term adverse 
effects, and 
(d) the merits and demerits of alternative thera-
pies. 
A common misconception is that a patient 
is assumed to have consented for treatment if he 
seeks medical consultation and subsequently pur-
chases the prescribed medication; in other words, 
the acceptance of treatment has been a voluntary 
act on his part. Thus, the responsibility for seek-
ing information about the benefits and risks of 
the treatment are implied to lie with the patient. 
In reality, nothing could be further wrong. The 
onus for education should lie with the clinician. 
Consider the risk for agranulocytosis with 
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clozapine therapy (Bleehen, 1993). Every clini-
cian will recognize the need for vigorous expla-
nations to the patient about the role of clozapine, 
the benefits and risks involved, and the precau-
tions to be taken. 
Why this especial concern with clozapine? 
Obviously, because the patient's life may be at 
stake. Extending the same logic, should not the 
patient's general medical and psychological well-
being be of equal concern? And, has not the 
patient a right to be aware of an intervention that 
involves his body? Thus, the clinician should 
consider it his personal responsibility to discuss 
the details of his prescription with the client. 
There are several reasons why informa-
tion should be made available by the clinician: 
* the patient has a legal and moral right to 
know what is being done to his body, and to 
participate in decision-making processes; 
* a well-informed patient is more likely to 
be compliant, cooperative, and participative in 
the therapeutic process than an poorly-informed 
patient (Fawcett, 1995); 
* the provision of proper informed con-
sent to treatment will protect the legal interests of 
the clinician. 
What information should be incorporated 
into the elements that I have suggested for my 
model? It goes without saying that the patient 
and/or a key relative should be aware of the 
diagnosis and the implications thereof. A brief 
explanation of the nature of the illness and of the 
manner in which the drug therapy is believed to 
act will justify the need for the prescription and 
will form the basic structure for a compliant 
attitude. 
An explanation of the likely benefits from 
the prescription and a provision of a time frame 
for expected events will reduce the risk for non-
compliance due to unrealistic expectations. 
An explanation of the possible adverse ef-
fects of therapy is essential because adverse 
effects with psychotropic medications are far 
more frequent than adverse effects with drugs 
commonly used in general medical practice; in 
consequence, a patient who is not warned about 
adverse effects may, on experiencing these, con-
sider that he is a victim of carelessness, or of 
bad prescribing, or of professional incompe-
tence. The risks for both short-term and long-
term adverse effects need to be described, and 
the availability of treatment for these adverse 
effects detailed. 
Finally, alternative therapies need to be 
discussed. These may include drugs other than 
those that have been prescribed, somatic thera-
pies instead of drugs, psychological therapies 
instead of drugs, alternate systems of medicine 
instead of the allopathic medical model etc. Due 
weightage needs to be given to the situation in 
which other lines of treatment are decidedly 
inferior to that prescribed; for example, 'coun-
selling' alone can never be a viable alternative to 
neuroleptic therapy for a schizophrenic patient. 
The education provided should not con-
fuse, frighten or overwhelm. Hence, especially 
in our country, flexibility in the provision of 
information is necessary. This is because pa-
tients and their relatives vary in their capacity to 
understand the implications of information, and 
this variance is a function of their education, 
their cultural background, their mood state, their 
level of preparedness etc. 
So, the psychoeducational and the 
pharmacoeducational process may need to be 
distributed (in content and depth) over several 
meetings, depending upon the patient's capacity 
to understand at that session, his recall of the 
education provided at the previous sessions, etc. 
It is emphasized that patients and their relatives 
will not remember everything that has been con-
veyed to them in earlier sessions, and so a degree 
of repctitiveness is necessary. Information should 
be provided with patience, and as often as is 
necessary. 
Such a psychoeducational and 
pharmacoeducational model, particularly insofar 
as it includes the family, impacts significantly 
and favourably on prognosis of disorders such 
as schizophrenia (Leff, 1985). With nearly two 
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decades of experience in psychoeducation at the 
Family Psychiatric Centre at NIMHANS, I can 
aver that my experiences have been similar. And, 
my experiences with the pharmacoeducational 
model have also been very positive, indeed. 
In my discussion so far, it was implicit 
that education is provided during face to face 
contact between clinician and clients; tlie medi-
um of communication is oral, and the clients 
have the opportunity to clarify their doubts. There 
is a less efficient alternative (which should there-
fore be used in addition to and not instead of oral 
pharmacoeducation), but one which may have 
greater legal validity, and which we must there-
fore definitely consider. In certain countries, the 
mental health services offer prepared documents 
that describe important aspects of specific drug 
therapies. For example, tlie Health and Commu-
nity Services, Victoria (Australia), prepares Sim-
ple Language Information for People on 
Psychotropics (SLIPPs; Baker, 1994); there are 
different SLIPPs for lithium therapy, for 
neuroleptic therapy, for tricyclic antidepressant 
drug therapy etc. 
If such documents are developed for Indi-
an practice, at least legally the practitioner may 
have discharged his responsibility - particularly if 
the patient signs receipt of the documents in a 
register maintained by the practitioner. 1 consider 
this practice to be essential with clozapine thera-
py; by extension, I see no reason why tlie same 
processes cannot be applied to all somatic thera-
pies in psychiatry. In effect, no patient can say, 
"I was not told about these side effects of the 
drug." Receipt of the educational material and 
subsequent acceptance of therapy is a reasonable 
index of the patient having consented to treat-
ment. 
The only clear disadvantage of providing 
information about the treatment is that the patient 
may, on learning about potential adverse effects, 
imagine that he has developed one, or attribute a 
natural event to a drug effect. A good therapist-
patient relationship should minimize tlie risk for 
such a possibility. The therapist can always clear 
up the patient's anxieties as and when they arise. 
It is a pity that little empirical work has 
been done in these areas in Indian psychiatry. 
We particularly need to know 
(a) what patients and their relatives want to 
know, 
(b) how best this information may be provided 
to them, 
(c) how much they can understand, 
(d) how much they recall, and, 
(e) the manner and extent to which they are 
influenced by the information. 
So far, I have been dealing with generali-
zations. There are certain special problems which 
need deeper consideration; 
1) Who should provide informed consent - the 
patient or his legal guardian? To what extent is 
the answer dependant on die patient's age, diag-
nosis, and other sociodemographic variables? 
Should consent provided by a relative be repeat-
ed with the patient at a time when the patient is 
recovering or recovered? 
2) Everyone will agree that provision of 
written consent for treatment is virtually the 
norm with electroconvulsive therapy. Most will 
also agree that consent for disulfiram treatment 
in the management of alcohol dependance should 
also be obtained in writing. Psychiatry is a branch 
of medicine which preys on sensitivities such as 
civil rights and freedom of choice; therefore, 
should consent be obtained in writing in other 
situations also, particularly when there is a risk 
for more serious or irreversible adverse effects? 
These include agranulocytosis with clozapine 
therapy, a potentially lethal adverse effect the 
risk for which is 0.8% (Bleehen, 1993), and 
tardive dyskinesia, the prevalence of which is 
estimated to be approximately 20% in schizo-
phrenic patients receiving long-term neuroleptic 
therapy (Barnes, 1985). 
3) For inpatient practice but almost never 
in outpatient situations, a number of hospitals 
routinely use a blanket consent form of tlie 
structure "I, tlie undersigned, agree to undergo 
'ABC procedures and receive 'XYZ' treatments 
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should my doctor consider it necessary for the 
management of my condition." Such a consent 
form is morally untenable: it tells the patient 
nothing, and does not prove that any (general or 
specific) information has been provided to the 
patient. Again, the onus is on the patient to obtain 
information from the clinician prior to signing. 
There is also the possibility that such a consent 
form may be legally untenable if the patient claims 
that he was not informed about 'PQR' effects. 
While it is obvious that the consent form will 
have to be context-specific, what should be the 
structure of the form, and how much informa-
tion should it contain? 
Regrettably, there are no satisfactory an-
swers to these issues. Mr. President, Sir, I be-
lieve that it is the responsibility of our society to 
evolve guidelines that will stand the test of law. 
Quality of Care 
In continuation with my discussion on the 
quality of psychiatric care: although the focus of 
my address lies on the pharmacotherapy of the 
patient, we would do well to consider the eight 
essential elements of quality in medical services 
that have been defined by the Council on Medical 
Service, American Medical Association (1986). 
In brief, care of high quality should 
a) produce the optimal improvement in the 
patient's physiological status, physical function, 
emotional and intellectual performance and com-
fort at the earliest time possible consistent with 
the best interests of the patient; 
b) emphasize the promotion of health, the 
prevention of disease or disability, and the early 
detection and treatment of such conditions; 
c) be provided in a timely manner, without 
undue delay in initiation of care, inappropriate 
curtailment or discontinuity, or unnecessary pro-
longation of such care; 
d) seek to achieve the informed coopera-
tion and participation of the patient in the care 
process and in decisions concerning that proc-
ess; 
e) be based on accepted principles of med-
ical science and the proficient use of appropriate 
technological and professional resources; 
f) be provided with sensitivity to the stress 
and anxiety that illness can generate and with 
concern for the patient's overall welfare; 
g) make efficient use of the technology 
and other health system resources needed to 
achieve the desired treatment goal; and 
h) be sufficiently documented in the pa-
tient's medical record to enable continuity of 
care and peer evaluation. 
In this context, the psychiatrist must give 
due consideration to the question, "Does the 
patient require a prescription at all?" In many 
situations, such as mild depressive and anxiety 
disorders, quality care may be better provided 
through psychological forms of therapy than 
through drugs; regrettably, benzodiazepines are 
often prescribed for such patients, later leading 
to withdrawal problems in the unfortunate pa-
tients. Family therapy is also one of my areas of 
especial interest; although distant from the theme 
of this oration, I would like to add here that 
quality care in psychiatry includes the involve-
ment of the family in the management plan 
(Channabasavanna, 1992). 
The importance of a strong therapeutic 
relationship with the patient and his family has 
been well brought about by the Pittsburg experi-
ence which focuses on alliance, not compliance, 
as a philosophy of outpatient care (Frank et al., 
1995). Using education and psychotherapeutic 
measures focusing on the index patient, his fam-
ily and friends, resulted in patient dropout rates 
below 10%, and compliances rates over 85% 
during multiyear trials. These are impressive sta^ 
tistics, indeed. 
While the Supreme Court judgement to 
which I had earlier referred would apply only in 
circumstances in which the psychiatrist had failed 
to exercise a due degree of care and competence 
in his services, I believe that if these quality of 
care guidelines are followed in the general man-
agement of all cases, and if the psychiatrist is 
adequately knowledgeable in his art as well as 
sufficiently conscientious in his application, it 
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will be hard to lose a medical malpractice suit. 
From the legal standpoint, I particularly underline 
the need to maintain records that meticulously 
detail decision-making processes in 
pharmacotherapy. 
In order that a reference standard be avail-
able as a yardstick to measure the quality of care, 
consensus statements are required that sum up 
the state of the art in the management of different 
psychiatric disorders, or in the use of different 
psychotropic medications. Such consensus state-
ments have already been made available for the 
use of electroconvulsive therapy (Freeman et al., 
1989; American Psychiatric Association, 1990), 
for the treatment of affective disorders (Consen-
sus Development Panel, 1985; American Psychi-
atric Association, 1994) etc. Mr. President, Sir, it 
is time that our society took up the responsibility 
for framing such consensus statements for appli-
cation in the Indian context. I am willing to take 
up at least some of the responsibility at NIMH ANS, 
if my suggestion is found meaningful by this 
august society, and I am sure that our society 
will not find it hard to find more volunteers. 
Improvement in treatment strategies 
Availability of consensus statements will 
provide to the clinician information about the 
current status in several fields, and of improved 
treatment strategies. Pharmacotherapy is too vast 
a field for me to provide a comprehensive per-
spective, but, in this context, there are certain 
aspects of drug therapy that I would particularly 
like to consider by way of examples of what I 
mean. 
When a prescription is written, due con-
sideration must be given to the choice of drug. 
This is not such an obvious issue as it appears. 
For example, with regard to the efficacy of anti-
depressant therapy, although all drugs are con-
ventionally considered to be equi-efficacious, there 
has very recently been some opinion that the 
selective serotonergic reuptake inhibitors (SSRIs) 
are less effective than conventional drugs in the 
management of melancholic depression (Roose 
et al., 1994). Many cumbersome interventions 
have been proposed for patients with refractory 
depression; venlafaxine, as yet unavailable in 
India, is a simpler alternative that has been found 
particularly effective in refractory depression 
(Montgomery, 1993; Nemeroff, 1994). 
With regard to adverse effects, the SSRIs 
are probably better tolerated than the conven-
tional antidepressant drugs. SSRIs lack sedative 
and anticholinergic action, and are relatively safe 
in overdose; this has led some authors to suggest 
that older tricyclics should not now be consid-
ered as a first-line treatment for depression 
(Montgomery, 1988); or even that drugs such as 
amitriptyline and imipramine should no longer be 
used in either clinical practice or clinical trials 
(Chouinard, 1985). While this opinion may be 
somewhat drastic, it is undeniable that 
amitriptyline is the most anticholinergic and se-
dating of the available antidepressants, and is 
therefore likely to occasion the patient more 
discomfort than other drugs. Clomipramine is 
also unlikely to be a good first line treatment for 
depression because of its effect on sexual func-
tioning; in one study, 100% of patients devel-
oped sexual problems with this drug (Monteiro 
etal., 1987). 
The SSRIs and clomipramine are both 
recommended for the treatment of obsessive 
compulsive disorder; clomipramine is, however, 
likely to be the drug of choice. A recent meta-
analysis found that effect size with clomipramine 
was substantially higher than that with the SSRIs 
(Greist et al., 1995). 
Buspirone has been an unpopular anxiolytic 
in India; at least one pharmaceutical company 
which marketed buspirone has now withdrawn 
the drug from sales. Yet, buspirone, and not a 
benzodiazepine, is surely the ideal drug for gen-
eralized anxiety disorder. It does not sedate, 
does not impair cognitive or psychomotor func-
tioning, does not interact with alcohol and does 
not produce dependance (Sussman, 1994). The 
last-mentioned is a particular advantage; 
benzodiazepine discontinuation syndromes (re-
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bound anxiety; withdrawal symptoms; relapse of 
anxiety) are serious clinical problems that force a 
patient into chronic therapy with the drug (Noyes 
et al., 1988; Salzman, 1991). 
Its advantages notwithstanding, buspirone 
is probably less effective if somatic anxiety symp-
toms are prominent. This is because a metabolite 
of buspirone, 1-pp, is an alpha-2 adrenergic 
receptor antagonist which enhances noradrenergic 
neurotransmission, thus potentially increasing so-
matic anxiety; buspirone is therefore best re-
served for patients in whom psychic anxiety is 
dominant (Sussman, 1994). Clinicians using 
buspirone should be patient because of the delay 
of a fortnight in its onset of action, particularly 
when upward dose titration is required. The lack 
of sedation with buspirone is also viewed as a 
disadvantage by some. But: given the proper 
choice of patient and proper pharmacoeducation, 
buspirone and not a benzodiazepine may be the 
more ethical treatment. 
Chlorpromazine and thioridazine are both 
very sedating, very anticholinergic, and strong 
inducers of postural hypotension mediated by 
blockade of alpha-1 adrenergic receptors. There 
is little scope for the use of these drugs except 
early in therapy, when the psychotic patient is 
disturbed and requires a degree of sedation. The 
availability of haloperidol decanoate, which occa-
sions even fewer adverse effects than its oral 
counterpart, which does not sedate, which has a 
duration of action of 4-6 weeks, and which is not 
characterized by a dumping effect (Simpson, 
1986) makes the conventional fluphenazine 
decanoate redundant; its only limitation is its 
cost. 
The availability of clozapine will change 
the way we view and treat schizophrenia in this 
country, for its efficacy in the severely ill, treat-
ment-refractory patient cannot be gainsaid (Kane 
et al, 1988). Particularly with this drug, some 
official guidelines should be made available, to 
protect the patient and the clinician. 
While on the subject of choice of drug, 
pharmacoeconomics is a matter for concern. By 
way of example, antidepressant drugs are availa-
ble that cost as little as a rupee or as much as 
Rs.20 for a day's supply. Clearly, the clinician's 
prescription must be governed as much by the 
patient's purse as by the patient's need. The 
obvious issues at stake are that the expense of 
medication should neither predispose to non-
compliance nor to financial burden and hence 
further stress on the patient or family. In this 
regard, the clinician must be capable of resist-
ance to the marketing pressure from the phar-
maceutical industry. 
In general, the older psychotropic agents 
are less expensive than the more recent ones. 
The older agents, while equipotcnt, are also more 
likely to occasion adverse events during therapy. 
However, 'newer' does not necessarily mean 
'better': a recent article stressed that the benefits 
of new (antidepressant) drugs are exaggerated 
(Owens, 1995), and, at the recently concluded 
World Psychiatric Association Section Meeting 
on Biological Psychiatry (Bombay, 1996), much 
of the discussion at the Symposium on Recent 
Antipsychotic Drugs also concluded as much. 
Why are the newer drugs so expensive? It 
is because the costs of drug development are 
being recovered. With the liberalisation of the 
economy, a question that wc must seriously 
consider is: to what extent should underdevel-
oped countries participate in the recovery of the 
research and development investments made by 
profit-based industries in the developed world? 
I have already pointed out that 'newer' 
does not necessarily mean 'better'. I also wish 
to stress that 'more expensive' does not mean 
'better', either; there is some food for thought 
here. The bottomline is that a more expensive 
drug warrants prescription only if there is a 
specific indication for it, and. of course, if it is 
affordable to the patient. 
A point worthy of note is that tardive 
dyskinesia was not recognized as an adverse 
effect of neuroleptic therapy until over a decade 
had elapsed since the introduction of these drugs. 
And, although clozapine was synthesized in 1958, 
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its propensity to produce agranulocytosis was 
not fully understood until the Finnish epidemic of 
1975 (Bleehen, 1993). The moral is that the older 
psychotropic agents have been with us longer, 
and we therefore understand their beneficial and 
adverse effect profile better than we understand 
that of the newer drugs. This is a matter particu-
larly to be kept in mind when prescribing to the 
pregnant or the lactating woman. 
Other issues in the choice of drug for 
therapy also beg attention; however I now move 
to the schedule of administration of the drug. In 
order to enhance compliance, the fewest number 
of doses should be administered per day. Regret-
tably, I still see theses and papers published in 
this country where neuroleptic and antidepres-
sant drugs have been administered in twice or 
thrice daily schedules. Such prescriptions also 
abound in clinical practice. There is no advantage 
in prescribing a neuroleptic more often than once 
at nighttime, unless it is to sedate a disturbed 
patient. 
Similarly, lithium is increasingly being pre-
scribed once daily (Bramble, 1992; Kehoe and 
Mander, 1992). This schedule increases compli-
ance, decreases the total daily dose requirement, 
decreases the renal adverse effects and is as 
effective as divided dose lithium (Plenge and 
Mellerup, 1986; Mellerup and Plenge, 1990; 
Suresh et al., 1994). 
During prescribing, a consideration of im-
portance is that poly drug therapy should be avoid-
ed at all costs unless absolutely necessary - such 
as when the patient has comorbid disorders, or 
when the drug combination results in a favoura-
ble interaction. Examples of favourable interac-
tions are the synergism of lithium and 
carbamazepine in the prophylaxis of affective 
disorders, and the use of anticholinergic drugs to 
counter the adverse effects of neuroleptics. An-
other such favourable interaction has come from 
the recent observation that the combination of 
fluoxetine with a conventional heterocyclic anti-
depressant drug may be effective in refractory 
depression (Zajecka et al., 1995). Favourable 
drug interactions in psychiatry are few. 
In other circumstances, polydrug therapy 
militates against the patient's well-being. It in-
creases the cost of therapy. It increases the risk 
for contusion in taking the medication, particu-
larly when the patient is elderly. It increases the 
risk for physiological adverse effects, particular-
ly when there is medical comorbidity. It increas-
es the risk for adverse drug interactions. It may 
interfere with the role of other components of 
the prescription; for example, you are all aware 
that fluoxetine increases blood levels of most 
other psychotropic substances, thus increasing 
the risk for drug toxicity, and that carbamazepine 
reduces blood levels, thus reducing the potential 
efficacy of the drug (Andrade, 1995; Ciraulo et 
al., 1995). 
Unless there is a specific indication, 
polydrug therapy constitutes irrational prescrib-
ing. I particularly question two sorts of irrational 
polydrug prescribing that I commonly encoun-
ter. One is the combination of different tricyclic 
antidepressant drugs. This is probably done with 
the view that the combination will have a 
synergistic therapeutic effect, or that the patient 
will tolerate the combination better than if only 
one drug were to have been prescribed in a 
higher dose, or that if the patient is a nonresponder 
to one of the two at least he will respond to the 
other. Such logic is specious, and, I stress, has 
no empirical support in the research literature. It 
is far more likely that all the difference that the 
patient will experience with the combination is 
an increased risk for adverse effects. 
The other common irrational prescription 
that I often see is the combination of a neuroleptic, 
an antidepressant, and a benzodiazepine. The 
purpose of such a combination is baffling. Does 
the clinician believe that the prescription will 
have a shotgun effect in cases of diagnostic 
uncertainty? I however note that in schizophren-
ic patients, the combination of a neuroleptic with 
a benzodiazepine, or of a neuroleptic with an 
antidepressant drug, may sometimes be indicat-
ed (Anant and Solano, 1993). 
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I may add that unless the patient is an 
alcoholic or has evidence of nutritional deficien-
cy, the inclusion of multivitamins in the prescrip-
tion is also irrational. The placebo may be a 
useful tool in medicine (Chaput de Saintonge and 
Herxheimer, 1994), but this does not endorse 
routine placebo prescriptions of vitamin prepara-
lions particularly when a psychotropic active 
ingredient is present in the same prescription. 
Moving on to fixed drug combinations: the 
only advantage with these is that the number of 
different pills that the patient has to swallow 
becomes fewer. The disadvantages are many; 
one is that the clinician does not have the oppor-
tunity to titrate the combination to the individual 
patient's requirement; another is that an element 
of the combination may not really be necessary; a 
third is that the risk for drug interactions and for 
adverse effects increases. Occasionally, the fixed 
combination of a neuroleptic and an anticholinergic 
drug may be countenanced; however, how can 
there be a justification for the fixed drug combi-
nation of two neuroleptics and an anticholinergic 
drug, or of a tricyclic antidepressant and a 
benzodiazepine? Yet, such are available in India. I 
wonder how many other countries permit the 
marketing of fixed psychotropic drug combina-
tions. 
These are but a few examples; there are 
several other fundamental aspects of prescribing 
that impinge on quality of care. These include the 
choice of starting dose and The rate of incre-
ments, the duration of therapy, the use of aug-
mentation strategies, the management of non-
response etc. I regret that time does not permit 
me to touch upon all that I wish to say. In this 
oration, I merely have the opportunity to sensitize 
clinicians to the importance of issues in prescrib-
ing in the quality of psychiatric care. Perhaps I 
may conclude this section with a comment on 
targeting symptoms for response. 
I believe that there is a role for the routine 
application of rating scales in the management of 
all patients. There are several reasons for this: 
rating scales permit the 
* identification of target symptoms for treat-
ment, and the assessment of change in the se-
verity of such symptoms over lime, 
* determination of the endpoint of treatment 
* documentation of response or non-response 
* objective description of the patient's clinical 
status, should it be required for legal purposes. 
In my experience, two practical uses for 
the routine application of rating scales are: 
1. Many patients stress areas in which 
they have not improved, and generalize the re-
port of their distress to other areas of function-
ing. This is known as a 'halo effect'. Use of a 
rating scale systematically assesses all areas of 
functioning, and draws the patient's attention to 
the areas in which response is observed. This 
impacts positively on the patient's morale, and 
enhances his confidence in his therapist. 
2. The systematic assessment of all areas 
of functioning draws the clinician's attention to 
areas in which response is sluggish. Interven-
tions targettcd to these areas can then be con-
ceived. The psychiatrist's confidence in his clin-
ical acumen is enhanced, and his clinical skills 
honed. 
Useful tools are the Hamilton Rating Scale 
for Depression, the Hamilton Anxiety Scale and 
the Brief Psychiatric Rating Scale. With a little 
experience, the clinician should be able to score 
the patient on the basis of the interview that he 
anyway conducts at each meeting with the pa-
tient; the extra time committment, therefore, will 
not exceed a few minutes per occasion. This 
time expenditure is well worth it. 
The pharmaceutical industry and 
prescription 
As I reach the conclusion of my address 
to you, I wish to discuss concerns that have 
been expressed from my institute about the role 
of the pharmaceutical industry in prescription 
communication and in drug quality. 
The first concern lies in the striking simi-
larity of the brand names of several different 
psychotropic medications, often belonging to 
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different drug classes. Some examples are: Elewal 
is doxepin, while Eliwel is amitriptyline; Mezatil is 
chlorpromazine, while Mazetol is carbamazepine; 
Anxipar is buspirone, while Anxipax is alprazolam 
etc. I am sure that you will all be aware of several 
other examples; a detailed list of different drugs 
that have similar names has been published in the 
Indian Journal of Psychiatry (Shamasundar, 
1992). 
This unfortunate state of affairs will cer-
tainly lead to some degree of confusion at the 
time of drug dispensation, and may result in the 
patient receiving a wrong treatment; in fact, that 
such has occurred is already on record (Andrade, 
1996). In view of the proliferating number of 
corporate bodies entering the pharmaceutical seg-
ment in this country, there is every likelihood that 
the problem will only increase. A possible solu-
tion is the use of the generic name of the drug on 
the prescription. 
But, and this is my second concern, the 
use of a generic name may introduce problems of 
its own. Generic drugs are manufactured by 
small pharmaceutical concerns which, due to 
budgetary constraints, may make certain com-
promises during the expensive and complex drug 
purification processes. These compromises can 
result in organic and inorganic impurities that 
may be present in excess of 1% in the final 
formulation; multinational companies usually re-
quire a purity of at least 99.8%. An excess of 
drug impurities may result in drug rashes, 
gastrointestinal disturbances, liver toxicity, 
teratogenic effects and, in rare cases in the long 
run, possibly in malignancy, too (Andrade, 1995). 
I hasten to add that such problems are not unique 
to India. Neppe et al. (1988) observed that in the 
U.S.A., adverse effects are commoner with ge-
neric carbamazepine than with the branded drug. 
While on the subject of quality control, I 
also wish to note that there is no assurance that 
with generic drugs the content of the active 
ingredient in the marketed preparation is as spec-
ified. Although necessary, it is not feasible for the 
state drug control authorities to conduct suffi-
cient random checks on all batches of all drugs 
of all the pharmaceutical companies in the coun-
try. Inevitably, some substandard medicines reach 
the general public. This consideration, too, must 
influence us in the choice of generic drugs ver-
sus those marketed by reputed companies. Un-
fortunately, in India many of the major compa-
nies purchase their raw material from small man-
ufacturers of generic drugs; thus, the argument 
runs within a circle with no good solution in 
sight (Andrade, 1995). 
Conclusion 
I realize that to many of you this would 
seem to have been an unusual subject for an 
oration. However, I well recall the convictions 
of the late Dr. Murti Rao in the spheres of 
biological and administrative psychiatry; were he 
to have been amongst us today, I hope and 
believe that he would have endorsed many of the 
views that I have expressed. Contemporary In-
dian psychiatry needs to take stock of its pre-
scribing habits. Pharmacoeducation needs to be-
come as much a part of therapy as 
psychoeducation. The contents of the prescrip-
tion need to be based on sound academic princi-
ples. 
It would be well if the Indian Psychiatric 
Society would constitute a standing subcommit-
tee, or a permanent cell, to formulate consensus 
statements for pharmacoeducation, therapeutic 
practice, medicolegal guidance in 
pharmacotherapeutic matters, and for interac-
tion with the Drug Controller of India as well as 
the pharmaceutical industry. 
My role in this oration has, I hope, been 
provocative. I hope that the provocation has 
been sufficient for the challenges to be taken up. 
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